FDA Issues Complete Response Letter to Supernus for SPN-830, a Potential Treatment for Motor Fluctuations in Parkinson Disease

According to the letter, the FDA believes that the investigational apomorphine infusion device is not ready for approval in its current form.

Source link
#FDA #Issues #Complete #Response #Letter #Supernus #SPN830 #Potential #Treatment #Motor #Fluctuations #Parkinson #Disease